Abstract
Abstract: :
Purpose:: To determine whether Methicillin Resistant Staphylococcus aureus (MRSA) is sensitive to Vigamox (moxifloxacin 0.5%), a new fourth generation topical fluoroquinolone antibiotic Methods:10 clinical isolates and one ATCC strain of MRSA were utilized. A 0.5 McFarland standard 1 x 108 CFU/ml was prepared from fresh 18–24 hour cultures. Serial ten–fold dilutions of commercially available moxifloxacin was prepared in Mueller Hinton Broth. Within 15 minutes after the inoculum has been standardized, 1 ml was added to each tube. The final organism concentration in each tube was 1 x 105 CFU/ml. The inoculated tubes were incubated at 35 0C for 16–20 hours in an ambient air incubator. Results:There was 100% kill of all 11 strains of MRSA. Conclusions:While MRSA is not sensitive to moxifloxacin at levels achieved in serum, 100% kill was achieved with commercially available topical moxifloxacin
Keywords: antibiotics/antifungals/antiparasitics • microbial pathogenesis: experimental studies • bacterial disease